Price (delayed)
$1.005
Market cap
$47.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
$6.89M
Shattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck
There are no recent dividends present for STTK.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.